NanoSyrinx

NanoSyrinx is an innovative and adventure-driven synthetic biology company that specializes in the targeted intracellular delivery of biological molecules. Positioned as a pacesetter in the realm of biopharmaceuticals, NanoSyrinx endeavors to redefine the traditional paradigms of medication dispensation. With a prime focus on improving the bioavailability and effectiveness of biologic drugs, such as antibodies and peptides, the company aims to pioneer the next generation of intracellular medicine.

Embarking on a journey imbued with rigorous research spanning over a decade, NanoSyrinx is instrumental in exploiting the unique attributes of nature’s solutions to bioavailability concerns. The company's diligent mission revolves around the radical metamorphosis of how medicines are administered, delving into the nanoscopic universe. NanoSyrinx’s exemplary dedication doesn’t stop at scientific innovation but extends to its contribution to the larger scientific community. It has been recognized as the winner of the 2022 AbbVie UK Golden Ticket program and the CEO, Joe Healey, has contributed to significant scientific discourses at the Parliamentary and Scientific Committee discussions.

Attributed with blazing strides in the UK’s synthetic biology sector, NanoSyrinx stands out as an exciting company to watch. The business's commanding vision and relentless pursuit of innovation hold immense prospective significance for human health and the global biopharmaceutical industry. Offering an entirely new modality in drug delivery, NanoSyrinx is poised to potentially "change medicine forever", indicating the huge potential impact of this dynamic and pioneering entity. Notable recognition, like winning the 2022 AbbVie UK Golden Ticket program, demonstrates the firm's leadership and promising future in the development of cutting-edge therapies and technology platforms.

Connect